News Merck sets sights on Epstein-Barr virus jab with Opko deal Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.
News GSK wins the vote contest in FDA’s RSV vaccine panels Advisory committee votes unanimously that RSVPreF3 shot is effective, and 10-2 on safety.
News Pfizer’s RSV shot clears FDA adcomm; now it’s GSK’s turn There was debate about cases of Guillain Barré and the population of the phase 3 RENOIR trial.
News Protocol violations gut Pfizer’s Lyme disease shot study 50% of US patients in the VALOR study of VLA15 will be discontinued from the trial.
Oncology Partner Content 2nd Next Generation RNA Therapeutics Summit Bringing Next Generation RNA Therapies to Patients Fast
News RFK Jr unorthodox vaccine views on show in interview Robert F Kennedy Jr's controversial views on vaccines were on display this week during an interview that touched on delays to a COVID-19 shot review.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
